Home/MapLight Therapeutics/James A. Johnson, CPA
JA

James A. Johnson, CPA

Chief Financial Officer

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Social impairment in Autism Spectrum DisorderPhase 2
ML-104Treatment-resistant DepressionPreclinical
ML-225Cognitive impairment in Alzheimer's DiseasePreclinical
Undisclosed ProgramAnxiety DisordersDiscovery